Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGS-003-BLD
- Development stage
- Discontinued
- Lead developer
- SCM Lifescience
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
AGS-003-BLD is an autologous dendritic cell-based immunotherapy developed for the treatment of muscle-invasive bladder cancer. It is a personalized vaccine created by co-electroporating a patient's own dendritic cells with amplified tumor-derived RNA (encoding tumor-specific antigens) and synthetic CD40L RNA. This process is designed to stimulate a robust T-cell mediated immune response against the patient's specific tumor antigens. In clinical studies led by the Mayo Clinic, it has been evaluated as a neoadjuvant therapy in combination with gemcitabine and cisplatin prior to radical cystectomy. The platform was originally developed by Argos Therapeutics, but development for bladder cancer was terminated following the company's financial restructuring and the termination of the pilot clinical trial.
- Other names
- Tumor Cell-Derived Vaccine TherapyAutologous Dendritic Cell-Based Vaccine
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on AGS-003-BLD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGS-003-BLD.